Blog
Drug Target Encyclopedia Series (25) —PSCA
Release Time：
2025-12-24 13:27
PSCA is a GPI-anchored cell surface membrane protein belonging to the Ly-6 family, with highly restricted expression in normal tissues but strong upregulation in multiple epithelial cancers.
Its extracellular accessibility and tumor-selective expression make PSCA a validated and commercially attractive oncology membrane target.
High PSCA expression observed in:
- Prostate cancer (localized → metastatic → CRPC)
- Bladder cancer
- Pancreatic ductal adenocarcinoma (PDAC)
- Gastric cancer
Clinically, PSCA overexpression correlates with tumor progression, invasion, and poor prognosis, reinforcing its role as a functional tumor-associated antigen, not just a biomarker.
Disease & Drug Development Value
From a drug discovery perspective, PSCA offers several advantages:
- Cell-surface localization (ideal for antibody-based targeting)
- Limited expression in vital normal tissues
- Stable expression across disease stages
- Broad applicability across solid tumors
These characteristics position PSCA as a strategic target for next-generation solid tumor therapies, especially where classical immune checkpoints underperform.
Emerging Therapeutic Strategies Targeting PSCA
🧪 Monoclonal Antibodies (mAbs)
Anti-PSCA antibodies are designed to mediate ADCC / CDC, directly eliminating PSCA-positive tumor cells.
🧪 CAR-T & CAR-NK Therapies
PSCA is one of the most clinically advanced solid-tumor CAR targets, particularly in prostate and pancreatic cancers, with active efforts to overcome TME-associated suppression.
🧪 Antibody–Drug Conjugates (ADCs)
PSCA’s stable surface expression supports payload delivery strategies, enabling selective cytotoxicity in PSCA⁺ tumors.
🧪 mRNA & Cell Engineering Tools
mRNA-based platforms are increasingly used to:
- Rapidly validate PSCA constructs
- Optimize CAR design and signaling domains
- Model PSCA expression density and safety windows
- Support transient expression for early-stage screening
Key Development Challenges
- Solid tumor microenvironment immunosuppression
- On-target/off-tumor toxicity thresholds
- Heterogeneous PSCA expression across patients
- Need for robust translational models
Current R&D Focus
- Next-generation PSCA CAR-T with armored or switch designs
- Combination with checkpoint blockade or TME modulators
- ADC payload optimization
- Biomarker-driven patient stratification
- mRNA-enabled rapid prototyping and validation
🧠 Industry Takeaway
PSCA exemplifies a commercially mature yet innovation-rich membrane target—bridging antibodies, cell therapy, and nucleic-acid–enabled discovery.
For companies focused on solid tumor immunotherapy and translational efficiency, PSCA remains a high-confidence, high-value asset.
Need PSCA tools for your research?
Fill out the form below, or visit the link: to browse the complete list of available in-stock products.
E-mail：support@levostar.com
USA
16192 Coastal Hwy，Lewes, DE 19958
TEL：619-537-9202
China
A3-502 No.328, Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu, China 215123
TEL：0512-62888898